Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 3;27(21):7523. doi: 10.3390/molecules27217523

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Synergistic interactions between F5, F7, F5-SM or F7-SM with niraparib on HTB75 cell viability at 48 h (a–d) and F5 or F7 with niraparib on HTB161 cell viability at 48 h (e,f) following combined treatments. Synergy of cytotoxic activity was calculated, based on the Bliss independence drug interaction model. Control was vehicle control (1.50% v/v methanol + 0.90% v/v DMSO for HTB75 and 1.38% v/v methanol + 2.50% v/v DMSO for HTB161). Synergy was apparent when the experimental (observed) value of cell survival inhibition was higher than the calculated (expected) value. Delta values of observed minus expected are shown on the Y axis. Supplementary Tables S4 and S5 present the significantly different synergistic delta values of F5, F7, F5-SM or F7-SM with niraparib from all pair combinations according to the Tukey–Kramer honest significant difference test (n = 3; HSD; p ≤ 0.05).